Testing effects of glatiramer acetate and fingolimod in an infectious model of CNS immune surveillance

Cyd Castro-Rojas, Krystin Deason, Rehana Z. Hussain, Liat Hayardeny, Petra C. Cravens, Felix Yarovinsky, Todd N. Eagar, Benjamine Arellano, Olaf Stüve

Research output: Contribution to journalArticle

Abstract

Immune surveillance of the CNS is critical for preventing infections; however, there is no accepted experimental model to assess the risk of infection when utilizing disease-modifying agents. We tested two approved agents for patients with multiple sclerosis (MS), glatiramer acetate and fingolimod, in an experimental model of CNS immune surveillance. C57BL/6 mice were infected with the ME49 strain of the neuroinvasive parasite Toxoplasma gondii (T. gondii) and then treated with GA and fingolimod. Neither treatment affected host survival; however, differences were observed in parasite load and in leukocyte numbers in the brains of infected animals. Here we demonstrate that this model could be a useful tool for analyzing immune surveillance.

Original languageEnglish (US)
Pages (from-to)232-235
Number of pages4
JournalJournal of Neuroimmunology
Volume276
Issue number1-2
DOIs
StatePublished - Nov 15 2014

Keywords

  • EAE
  • Experimental autoimmune encephalomyelitis
  • Immune surveillance
  • Toxoplasma gondii

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Testing effects of glatiramer acetate and fingolimod in an infectious model of CNS immune surveillance'. Together they form a unique fingerprint.

Cite this